TABLE 1 .
Summary characteristics of the HIV-1–HTLV-1 dually infected group and the HIV-1-monoinfected control group
| Characteristic | HTLV-1–HIV-1 dual infection |
HIV-1 monoinfection |
|---|---|---|
| No. of subjects | 18a | 18 |
| Median age, yr (IQR)g | 46 (12) | 41 (10) |
| No. (%) with HIV riskb | ||
| Heterosexual | 3 (42.9) | 6 (33.3) |
| IDUh | 3 (42.9) | 4 (22.2) |
| Other | 1 (14.3) | 8 (44.4) |
| Median plasma HIV-1 RNA loadn (IQR) | 4.8 (1.05) | 5.0 (0.6) |
| No. (%)c with CVL HIV-1 RNA loadn of: | ||
| >1.7 | 4 (22.2) | 4 (22.2) |
| <1.7 | 2 (11.1) | 3 (16.7) |
| NDj | 4 (22.2) | 5 (27.8) |
| NAk | 8 (44.4) | 6 (33.3) |
| No. (%) with HTLV-1 RNA in plasmac | ||
| Detected | 1 (5.6) | 0 (0) |
| Not detected | 7 (94.4) | 18 (100) |
| No. (%) with positive HTLV-1 serostatusb,d | 7 (100) | 0 (0) |
| No. (%)c with CVL HTLV-1 RNA | ||
| Detected | 4 (22.2) | 0 (0) |
| Not detected | 14 (77.8) | 18 (100) |
| Median no. of CD4+ cells/µl (IQR)c | 151 (206.5) | 324.5 (317.5) |
| No. (%)e with ART use | 15 (83.3) | 2 (11.1) |
| No. (%) with LGTi infection | ||
| Oncogenic HPVf,l | 18 (100) | 16 (88.9) |
| HSVb,m | 18 (100) | 16 (88.9) |
| Bacterial vaginosisc | 2 (11.1) | 2 (11.1) |
| Candida vaginitisc | 1 (5.6) | 2 (11.1) |
a
Eighteen visits by seven HIV-1–HTLV-1-coinfected subjects were selected, two to four visits per subject.
b
Data from the enrollment.
c
Data from the time of sampling.
d
As determined by Telzak et al. (52).
e
Antiretroviral therapy (ART) in the past 12 months.
f
Data from the first few visits.
g
IQR, interquartile range.
h
IDU, intravenous drug use.
i
LGT, lower genital tract.
j
ND, not detected.
k
NA, data not available.
l
HPV, human papillomavirus.
m
HSV, herpes simplex virus.
n
Log number of copies per milliliter.